An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD

作者：Clement Fiona M; Klarenbach Scott; Tonelli Marcello; Wiebe Natasha; Hemmelgarn Brenda; Manns Braden J^*

来源：American Journal of Kidney Diseases, 2010, 56(6): 1050-1061.

DOI：10.1053/j.ajkd.2010.07.015

• Erythropoiesis-stimulating agents
• economic evaluation
• hemoglobin targets
• chronic kidney disease

Background: The objective was to determine the cost-effectiveness of treating anemic patients with chronic kidney disease (CKD) with erythropoiesis-stimulating agents (ESAs) to a low (9-10.9 g/dL), intermediate (11-12 g/dL), or high (> 12 g/dL) hemoglobin level target compared with a strategy of managing anemia without ESAs.
Study Design: Cost-utility analysis.
Setting & Participants: Publicly funded health care system. Anemic patients with CKD, overall and stratified into dialysis-/non-dialysis-dependent subgroups.
Model, Perspective, & Timeframe: Decision analysis, health care payer, patient's lifetime.
Main Outcome: Cost per quality-adjusted life-year (QALY) gained.
Results: For dialysis patients, compared with anemia management without ESAs, using ESAs to target a low hemoglobin level is associated with a cost per QALY of $ 96,270. Given a lack of direct trials comparing low and intermediate targets, significant uncertainty exists between these strategies. Treatment to a high hemoglobin target was always associated with worse clinical outcomes and higher costs compared with a low hemoglobin target. Results were similar in non-dialysis-dependent patients with CKD, with a cost per QALY for a low target compared with no ESA of $ 147,980.
Limitations: Given limitations in the available randomized controlled trials, we were able to model only 4 treatment strategies, balancing the need to consider relevant targets with the requirement for accurate estimates of clinical effect. We assumed that the efficacy of the different strategies would continue over a patient's lifetime.
Conclusions: Using ESAs to target a hemoglobin level > 12 g/dL is associated with worse clinical outcomes and significant additional cost compared with using ESAs to target lower hemoglobin levels (9-12 g/dL). Given a lack of studies comparing low (9-10.9 g/dL) and intermediate (11-12 g/dL) hemoglobin targets for clinical outcomes, including quality of life, the most cost-effective hemoglobin level target within the range of 9-12 g/dL is uncertain, although aiming for higher targets within this range will lead to higher costs. Am J Kidney Dis 56: 1050-1061.

• 出版日期2010-12